looking for an explantion about after hours trades in PENNYLAND

I always thought it wasn't possible, but then, I found HESG.pk

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70125576

if it is just MM's settling trades, why after hours??

if you dump shares at 5th digit after hours, they will not show up on FINRA short lists..

thanks to whomever replies

-Neb

Go PARD! It just hit 2 bucks premarket!

BCON

ACPW

ZIOP

APCVZ almost 2 mil in volume now, 10 Day Average Volume 140,962

APCVZ hit 1.19 and dipping again here! WEEEEEEE

1.13's hit's dang I sold too soon, DIP DIP DIP

APCVZ 1.11 now, no time to post earlier in the .90's it went so fast. News!

SUPER-SHIZZLER-CHARTS by DFB...these are stack em high and watch em fly !!!

AMNP....HUGE green candle..ACCUMULATION thru the roof!!



SNWT...accumulation kaboomy!!..parsar flipped!!



PCIR..this baby is gonna go..THIN THIN...and look at volume coming in..

UCBH (1.04) +.38, •China's Minsheng Seeks Control of UCBH
at TheStreet.com(Tue 1:35am)
•China's Minsheng eyes control of US bank UCBH- report
at Reuters(Tue 12:34am)

AVII 52 Week High (7/30/2009) 2.73

Thanks Di

AVII 1.98 GO BABY

Welcome! Glad to have you here!

:) We are trading the same one! GMTA ;)

Hi bl, It's just where I have my settings on news and filings for equity trade... otherwise you were right, the market is just too big to watch them all.

The bang for the buck is a good thing too ;)

But I'll be watching out for your higher price ones!

AVII 1.90

Monday, October 05 2009 8:01 AM, EST AVI BioPharma Receives Expanded Contract From U.S. Department of Defense to Develop Its Drug Candidate for the Treatment of Junin Virus Infection Market Wire    "US Press Releases "
BOTHELL, WA -- (MARKET WIRE) -- 10/05/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection. To date, the United States Department of Defense (DoD) has contracted with AVI for work potentially worth up to $45 million for the development of AVI's RNA-based drug candidates to treat Ebola, Marburg and Junin virus infections (AVI-6002, AVI-6003 and AVI-7012, respectively).

"AVI has recently been able to confirm the impressive and dose-related survival of drug-treated non-human primates in large dose titration studies for Ebola and Marburg virus infections, which were carried out in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)," said Dr. Patrick Iverson , Senior Vice President for Strategic Alliances at AVI. "Importantly, these studies allowed us to unequivocally demonstrate the sequence-specific nature of the protection afforded by our drug candidates."

AVI has received a 'safe to proceed' allowance from the United States Food and Drug Administration ( FDA ) for IND applications for clinical safety trials of its two lead products to treat Ebola and Marburg virus infections. These INDs represent the first TMTI supported drug candidates targeting bioterrorism agents to receive FDA IND allowance.

AVI plans to conduct the animal efficacy trials for potential approval of its drugs under the Animal Rule as part of its continued collaboration with USAMRIID. The majority of the collaborative research effort between AVI and USAMRIID has been supported by a research contract from the DoD's TMTI with the goal of developing a new antiviral platform targeting hemorrhagic fever viruses. The current funding is a second amendment and expansion of an original contract from DTRA, which was awarded in November 2006 for $28 million and has been fully authorized. The contract for the first amendment was issued in May 2009 when an additional $5.9 million was authorized to support continued development of AVI's RNA-based drugs AVI-6002 and AVI-6003 to treat Ebola and Marburg virus infections, respectively.

"The expansion of the contract for our therapeutic programs in Junin, Ebola and Marburg viruses reflects the DoD's continued support of our bio-defense program, which is developing a series of RNA-based anti-viral drugs," said David Boyle , Chief Financial Officer of AVI. "AVI's ability to virtually double the value of the original contract is a powerful illustration of the performance of our drug candidates to date."

AVI-6002, AVI-6003 and AVI-7012 are novel analogs based on AVI's PMO antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the morpholino oligomer backbone.

About DTRA & TMTI

DTRA was founded in 1998 to integrate and focus the capabilities of the DoD that combat the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and thereby mitigate its effects. Under DTRA, DoD resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats.

The TMTI was created by the DoD to protect the Warfighter from emerging and genetically altered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, test and evaluation programs. The TMTI Program Office is matrixed from the Joint Science and Technology Office -- DTRA and Joint Program Executive Office -- Chemical and Biological Defense, with oversight from the Office of the Secretary of Defense . For more information on TMTI, visit http://www.tmti-cbdefense.org.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland , is the lead medical research laboratory for the U.S. DoD Biological Defense Research Program. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the Warfighter. While USAMRIID's primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company . AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as the H1N1 strain of influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

AVI Press and Investor Contact: Julie Rathbun investorrelations@avibio.com (541) 224-2575


AVII,

Gets coverage by Barron's


Successful study may boost Avi BioPharma-Barron's
Sun Oct 4, 2009 6:22pm EDT

NEW YORK, Oct 4 (Reuters) - If Avi BioPharma's (AVII.O) drug for Duchenne muscular dystrophy proves successful, shares of this biotech are likely to surge, Barron's said on Sunday.

The company may also be an acquisition target for Big Pharma, the financial newspaper said. The drug is in early-stage trials in the United Kingdom and the results of that trial may be revealed late this year.

The Duchenne drug could garner $1 billion or more in annual revenue and if it moves toward U.S. Food and Drug Administration approval, the stock could leap.

But like many other biotechs, Avi BioPharma is a highly speculative play and the company has disappointed investors in the past, Barron's noted.

On Friday, the company's stock fell 4.3 percent to $1.56 on the Nasdaq. (Reporting by Deepa Seetharaman; Editing by Jan Paschal)

AVII (1.90) +.34, AVI BioPharma Receives Expanded Contract From U.S. Department of Defense to Develop Its Drug Candidate for the Treatment of Junin Virus Infection
$11.5 Million New Funding Brings Total Award to $45 Million

Press Release
Source: AVI BioPharma, Inc.
On Monday October 5, 2009, 8:00 am EDT
Buzz up! 0 Print.Companies:AVI Biopharma, Inc.
BOTHELL, WA--(Marketwire - 10/05/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection. To date, the United States Department of Defense (DoD) has contracted with AVI for work potentially worth up to $45 million for the development of AVI's RNA-based drug candidates to treat Ebola, Marburg and Junin virus infections (AVI-6002, AVI-6003 and AVI-7012, respectively).

Related Quotes
Symbol Price Change
AVII 1.56 0.00


{"s" : "avii","k" : "c10,l10,p20,t10","o" : "","j" : ""} "AVI has recently been able to confirm the impressive and dose-related survival of drug-treated non-human primates in large dose titration studies for Ebola and Marburg virus infections, which were carried out in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)," said Dr. Patrick Iverson, Senior Vice President for Strategic Alliances at AVI. "Importantly, these studies allowed us to unequivocally demonstrate the sequence-specific nature of the protection afforded by our drug candidates."

AVI has received a 'safe to proceed' allowance from the United States Food and Drug Administration (FDA) for IND applications for clinical safety trials of its two lead products to treat Ebola and Marburg virus infections. These INDs represent the first TMTI supported drug candidates targeting bioterrorism agents to receive FDA IND allowance.

AVI plans to conduct the animal efficacy trials for potential approval of its drugs under the Animal Rule as part of its continued collaboration with USAMRIID. The majority of the collaborative research effort between AVI and USAMRIID has been supported by a research contract from the DoD's TMTI with the goal of developing a new antiviral platform targeting hemorrhagic fever viruses. The current funding is a second amendment and expansion of an original contract from DTRA, which was awarded in November 2006 for $28 million and has been fully authorized. The contract for the first amendment was issued in May 2009 when an additional $5.9 million was authorized to support continued development of AVI's RNA-based drugs AVI-6002 and AVI-6003 to treat Ebola and Marburg virus infections, respectively.

"The expansion of the contract for our therapeutic programs in Junin, Ebola and Marburg viruses reflects the DoD's continued support of our bio-defense program, which is developing a series of RNA-based anti-viral drugs," said David Boyle, Chief Financial Officer of AVI. "AVI's ability to virtually double the value of the original contract is a powerful illustration of the performance of our drug candidates to date."

AVI-6002, AVI-6003 and AVI-7012 are novel analogs based on AVI's PMO antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the morpholino oligomer backbone.

About DTRA & TMTI

DTRA was founded in 1998 to integrate and focus the capabilities of the DoD that combat the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and thereby mitigate its effects. Under DTRA, DoD resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats.

The TMTI was created by the DoD to protect the Warfighter from emerging and genetically altered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, test and evaluation programs. The TMTI Program Office is matrixed from the Joint Science and Technology Office -- DTRA and Joint Program Executive Office -- Chemical and Biological Defense, with oversight from the Office of the Secretary of Defense. For more information on TMTI, visit http://www.tmti-cbdefense.org.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. DoD Biological Defense Research Program. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the Warfighter. While USAMRIID's primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as the H1N1 strain of influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

Contact:
AVI Press and Investor Contact:Julie Rathbuninvestorrelations@avibio.com(541) 224-2575

Chelsea Therapeutics Raised To Buy From Neutral By Ladenburg Thalmann >CHTP

So you trade mostly under $5. Curious about your reasoning?
More bang for your buck, not dependant on the market so much?
TIA

CHTP(3.05), +.54 on 860k vol, Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension
Press Release
Source: Chelsea Therapeutics
On Thursday October 1, 2009, 7:00 am EDT
Buzz up! 0 Print.Companies:Chelsea Therapeutics International Ltd.



Droxidopa Demonstrates Statistically Significant Improvement On 5
Clinically Meaningful Measures of Symptomatic Neurogenic
Orthostatic Hypotension

Exceptional Safety and Tolerability Validated

Related Quotes
Symbol Price Change
CHTP 2.51 0.00


{"s" : "chtp","k" : "c10,l10,p20,t10","o" : "","j" : ""}
CHARLOTTE, N.C., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP - News) announced that continued analysis of previously reported results from Study 302, the first of two pivotal Phase III trials in Chelsea's registration program of Droxidopa for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), confirm statistically significant benefits across five clinically relevant assessment criteria that reflect symptomatic improvements and corroborate other supportive symptom data. The collective dataset also supports the exceptional safety and tolerability of Droxidopa.



"We are encouraged by the breadth and depth of findings from Study 302 that demonstrate a symptomatic benefit and provide validation of the safety and tolerability of Droxidopa for the treatment of neurogenic orthostatic hypotension -- a serious condition with an urgent need for improved treatments," said Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. "In looking ahead, we believe these results will be evident in the results of Study 301 expected this quarter. Further, we believe the outcome of Study 301 may be enhanced by the washout period included in that study. This belief is supported by open-label data from Study 301 that demonstrate a marked return of symptoms prior to randomization. The increase in average dizziness score from 1.0 following dose titration to 5.4 after a 7-day washout period in Study 301 suggests a reduction in the carry-over effect that appeared to follow sustained drug treatment prior to randomized withdrawal in Study 302."



Statistically Significant Symptomatic Benefit on Multiple Endpoints



Patients randomized into this double-blind, placebo controlled study were evaluated for functional and symptomatic improvement through multiple secondary endpoints including a clinician-recorded and patient-recorded clinical global impressions-severity (CGI-S) scale and the orthostatic hypotension questionnaire (OHQ), a two part questionnaire consisting of the six-item orthostatic hypotension symptom assessment scale (OHSA) and the four-item orthostatic hypotension daily activities scale (OHDAS).



With the exception of vision, Droxidopa demonstrated a marked improvement over placebo for each of the five other symptoms measured by the OHSA (dizziness, weakness, fatigue, concentration, and head/neck pain) with the overall composite OHSA score supporting the benefit of Droxidopa over placebo. Despite indicating an improvement over placebo, Item 1 on the OHSA (dizziness), the primary endpoint in the study, did not achieve statistical significance.



On the OHDAS, a measure of patient function which asks patients to evaluate the average impact of orthostatic hypotension on their daily lives over the prior week period using an 11-point scale, Droxidopa demonstrated a statistically significant improvement in activities that require standing for a short time (p=0.043), standing for a long time (p=0.023) as well as a statistically significant improvement in the composite OHDAS score (p=0.029) which includes evaluation of standing and walking for both short and long times.



Notably, in addition to symptomatic and functional benefits registered on the OHQ, Droxidopa demonstrated statistically significant improvement on both the clinician-recorded (p=0.045) and patient-recorded (p=0.008) CGI-severity scale, a widely accepted scale that asks clinicians and patients to rate the severity of a patient's symptoms at the time of assessment.



"No other drug treatment has successfully demonstrated a statistically significant symptomatic and/or functional benefit in treating orthostatic hypotension," commented Dr. Art Hewitt, Vice President of Drug Development at Chelsea Therapeutics. "By achieving statistical significance on five secondary endpoints that reflect both a functional and symptomatic benefit, three of which were specifically developed for this indication, Droxidopa has clearly demonstrated its unique ability to meaningfully treat symptomatic neurogenic orthostatic hypotension. We look forward to discussing these results with the FDA, as we believe that results from Study 302 provide meaningful data supporting Droxidopa's efficacy and want to ensure we are taking all appropriate and actionable steps to ensure a successful NDA filing."



Proven Safety and Tolerability



As previously reported, Droxidopa proved to be safe and well tolerated at all dose levels, with no significant adverse events or treatment related withdrawals in the Droxidopa arm.



Of the 101 patients evaluated in Study 302 (50 Droxidopa/51 Placebo), an equal number of patients on Droxidopa and placebo, 13 (26%), experienced at least one instance of supine systolic blood pressure (SBP) >160 mmHg; six (12%) of Droxidopa patients experienced supine SBP >180 mmHg vs. four (8%) on placebo. No patients treated with Droxidopa experienced supine hypertension >200 mmHg compared to one (2%) patient on placebo. These findings, in light of the inherent prevalence of supine hypertension in patients with primary autonomic failure, demonstrate that treatment with Droxidopa does not meaningfully alter the incidence of supine hypertension in the patient group. In the product labeling for Midodrine, the only approved compound for the treatment of orthostatic hypotension, supine hypertension (> 200 mmHg) is reported at 13.4%.



In addition, treatment with Droxidopa demonstrates a dramatic improvement in the incidence of falls associated with orthostatic hypotension. In Study 302, six (12%) patients on placebo reported falling at least once during the 14-day treatment period compared to one (2%) patient in the Droxidopa arm. This marked reduction in falls, while recorded under adverse events for the study, further supports the significant symptomatic benefit experienced by patients treated with Droxidopa.



NOH Impacts Quality of Life, Increases Health Care Costs



Neurogenic orthostatic hypotension is a neurogenic disorder resulting from a deficient release of norepinephrine, the neurotransmitter used by sympathetic autonomic nerves to send signals to the blood vessels and the heart. This deficiency results in decreased blood pressure when a person assumes a standing position and is characterized by lightheadedness, dizziness, blurred vision and syncope.



An estimated 300,000 patients suffer from chronic symptomatic NOH in the U.S. and the EU. Symptoms of chronic NOH can be incapacitating -- not only putting patients at high risk for falls and associated injuries -- but also severely impacting the quality of life of patients and their loved ones, and generating significant health care costs. The only current FDA-approved treatment for orthostatic hypotension has not been shown to be effective in alleviating the symptoms of the condition and is limited in its use by a pronounced side-effect profile.



About Droxidopa and the Droxidopa Registration Trial in NOH



Currently available in Japan and with 15 years of safety and efficacy data, Droxidopa is the first drug to demonstrate symptomatic improvement of NOH. As an orally active synthetic precursor of norepinephrine, Droxidopa increases the supply of norepinephrine available for delivery to its receptors, effectively targeting the root cause of NOH to improve orthostatic blood pressure and alleviate symptoms of orthostatic hypotension.



The Droxidopa Phase III registration program in NOH includes two double-blind, placebo-controlled studies: Study 301 and Study 302. Study 301was reviewed by the U.S. Food and Drug Administration (FDA) and awarded a Special Protocol Assessment (SPA). An SPA provides a binding agreement that the study design, including trial size, clinical endpoints and/or data analyses is acceptable to support regulatory approval. In addition to the SPA, the FDA has awarded Chelsea Fast Track designation for its pivotal program in NOH. Fast Track designation is designed to facilitate the review of products that address serious or potentially life-threatening conditions for which there is an unmet medical need and provides the option to file a New Drug Application (NDA) on a rolling basis. This permits the FDA to review the filing as it is received, expediting the review process.



About Chelsea Therapeutics



Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX), currently the leading antifolate treatment and standard of care for a broad range of abnormal cell proliferation diseases including RA.



This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.






Contact:
Chelsea Therapeutics International, Ltd.Investors:Kathryn McNeil718-788-2856mcneil@chelseatherapeutics.comHill & KnowltonMedia:Sean Leous212-885-0549sean.leous@hillandknowlton.com

CTIC News / Announcement

OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Pot
Date : 10/01/2009 @ 1:30AM
Source : PR Newswire
Stock : (CTIC)
Quote : 1.23 0.0 (0.00%) @ 7:22AM

OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Pot

Phase II results to be presented at Proffered Session of International Society of Gastrointestinal Oncology

PHILADELPHIA, Oct. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

The phase II study, led by Dr. Safran, enrolled 40 patients with pathologically-confirmed, locally-advanced adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-esophageal junction with no evidence of distant metastasis. The patients received weekly paclitaxel poliglumex (50mg/m2) and cisplatin 25mg/m2 for six weeks with concurrent 50.5Gy of radiation. Of the first 28 patients undergoing surgery, all with adenocarcinoma, eight of 28 (28.5%), have achieved a pathologic CR. No patients required a feeding tube, in contrast to historical studies using the standard regimen where the large majority of patients require a feeding tube. There were no grade 4 hematologic toxicities; grade 3 hematologic toxicity included neutropenia (n=2) and anemia (n=1). Four of 35 patients experienced grade 4 non-hematologic toxicities, which included electrolyte abnormalities, glucose intolerance, hypersensitivity reaction and thromboembolus. Eleven of 35 patients had grade 3 non-hematologic toxicities including electrolyte abnormalities (n=5), nausea (n=3), dysphagia (n=2), fatigue (n=2), glucose intolerance (n=2), and hypersensitivity reaction (n=1). Grade 3 anorexia was reported in only one patient who subsequently was given total parenteral nutrition. No patients developed neuropathy.

"These are very promising results, as standard platinum, 5-FU, and radiation-based regimens for this disease are accompanied by a high incidence of severe radiation esophagitis, requiring patients to receive nutrition through feeding tubes," said Dr. Safran. "Paclitaxel poliglumex's selective radiation enhancement preclinical profile is being validated by the high rates of pathologic complete remission and low rates of severe regional side effects we have observed in this phase 2 study. Our results justify proceeding to a randomized, controlled trial to definitively prove the impressive clinical benefit we have observed in our experience with this novel bioengineered paclitaxel agent," Dr. Safran added.

"We look forward to discussing with the Food and Drug Administration a potential phase III registration strategy for this indication," said Jack Singer, M.D., Chief Medical Officer at CTI. "This would be the first registration study for a radiation sensitizing agent in this indication."

Concurrent chemotherapy with 50.5 Gy of radiation is the standard pre-surgical therapy for patients with potentially resectable, locally-advanced esophageal cancer. Although the addition of chemotherapy to radiation is beneficial, the cure rate for esophageal cancer is low. Standard neoadjuvant treatment for esophageal cancer uses a regimen of cisplatin, and fluorouracil (5-FU) chemotherapy with concurrent radiation, which is a regimen associated with a high incidence of Grade 3-4 toxicity to the upper gastrointestinal track necessitating prophylactic insertion of feeding tubes. Published preclinical studies have demonstrated that, unlike standard paclitaxel and other chemotherapeutic agents that enhance radiation killing by a factor of 1.5 to 2.0, OPAXIO increases tumor specific radiation cell kill by a factor of 7.2 to 8.4-fold (Milas Luka et al, Poly(L-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability, Int'l J. Radiat. Oncol. Biol. Phys. 55(3), 707-12 (2003)).

The presentation slides are available at http://www.celltherapeutics.com/investor_updates.

CTI has an existing license and co-development agreement with Novartis for OPAXIO, which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at our Web site, http://www.celltherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential for OPAXIO to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that OPAXIO will not produce high rates of complete remission in patients with advanced esophageal cancer, the possibility that the registration trial for OPAXIO as a radiation sensitizer will not occur, the possibility that the U.S. Food and Drug Administration will not approve a phase III registration strategy for paclitaxel poliglumex if proposed by CTI, the potential that Novartis will not exercise its option, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and selling OPAXIO. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian T: 206.272.4343 C: 206.854.1200 E: http://www.celltherapeutics.com/press_room

Investors Contact:

Ed Bell T: 206.282.7100 Lindsey Jesch Logan T: 206.272.4347 F: 206.272.4434 E: http://www.celltherapeutics.com/investors

Medical Information Contact:

T: 800.715.0944 E:

DATASOURCE: Cell Therapeutics, Inc.

CONTACT: Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,

, or investors, Ed Bell, +1-206-282-7100, or Lindsey

Jesch Logan, +1-206-272-4347, fax, +1-206-272-4434, , all

of Cell Therapeutics, Inc.; or Medical Information, 1-800-715-0944,

Web Site: http://www.celltherapeutics.com/

Great Idea Di, marked ya.

XOMA .814 XOMA Announces $13.9 Million Financing GlobeNewswire    "GlobeNewswire "
BERKELEY, Calif. , Sept. 30, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the sale of 18 million of its common shares to Azimuth Opportunity Ltd. for gross proceeds of $13.9 million , or approximately $0.77 per share, under its existing committed equity financing facility with Azimuth. The Company intends to use the net proceeds from this sale to continue development of its XOMA 052 product candidate, for other general corporate purposes and for working capital. Based on its cash reserves including the proceeds from this offering, anticipated revenues from collaborations including a XOMA 052 corporate partnership, licensing transactions and biodefense contracts, XOMA believes it has sufficient cash resources to meet its anticipated net cash needs into 2011.

"We are pleased to have significantly strengthened our financial position through this offering and the elimination of substantial debt, as announced last week," said Steven B. Engle , XOMA Chairman and Chief Executive Officer. "In addition, we recently entered into a $6 million technology collaboration with a subsidiary of Cephalon Inc. and expanded our biodefense business with a new contract for development of an antibody to influenza viruses including the H1N1 and H5N1 strains. These developments strengthen our financial position as we pursue additional collaborations including a XOMA 052 corporate partnership and other antibody technology collaborations."

The securities described above were sold by XOMA Ltd. pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About XOMA

XOMA discovers, develops and manufactures therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody in development for Type 2 diabetes and cardiovascular disease, and XOMA 3AB, a biodefense anti-botulism antibody candidate.

The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960

Forward-looking Statements

Certain statements contained herein concerning the sufficiency of our cash resources or product development or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Among other things, the period for which our cash resources are sufficient could be shortened if expenditures are made earlier or in larger amounts than anticipated or are unanticipated, if anticipated revenues or cost-sharing arrangements do not materialize, or if funds are not otherwise available on acceptable terms. These and other risks, including those related to inability to comply with NASDAQ's continued listing requirements, the declining and generally unstable nature of current economic conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA , European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.

CONTACT: XOMA Company and Investor Contact: Carol DeGuzman 510-204-7270 Cell: 510 717 4642 deguzman@xoma.com Porter Novelli Life Sciences Media Contact: Carolyn Hawley 619-849-5375 chawley@pnlifesciences.com

XOMA .814 XOMA Announces $13.9 Million Financing GlobeNewswire    "GlobeNewswire "
BERKELEY, Calif. , Sept. 30, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the sale of 18 million of its common shares to Azimuth Opportunity Ltd. for gross proceeds of $13.9 million , or approximately $0.77 per share, under its existing committed equity financing facility with Azimuth. The Company intends to use the net proceeds from this sale to continue development of its XOMA 052 product candidate, for other general corporate purposes and for working capital. Based on its cash reserves including the proceeds from this offering, anticipated revenues from collaborations including a XOMA 052 corporate partnership, licensing transactions and biodefense contracts, XOMA believes it has sufficient cash resources to meet its anticipated net cash needs into 2011.

"We are pleased to have significantly strengthened our financial position through this offering and the elimination of substantial debt, as announced last week," said Steven B. Engle , XOMA Chairman and Chief Executive Officer. "In addition, we recently entered into a $6 million technology collaboration with a subsidiary of Cephalon Inc. and expanded our biodefense business with a new contract for development of an antibody to influenza viruses including the H1N1 and H5N1 strains. These developments strengthen our financial position as we pursue additional collaborations including a XOMA 052 corporate partnership and other antibody technology collaborations."

The securities described above were sold by XOMA Ltd. pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About XOMA

XOMA discovers, develops and manufactures therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody in development for Type 2 diabetes and cardiovascular disease, and XOMA 3AB, a biodefense anti-botulism antibody candidate.

The XOMA Ltd. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5960

Forward-looking Statements

Certain statements contained herein concerning the sufficiency of our cash resources or product development or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Among other things, the period for which our cash resources are sufficient could be shortened if expenditures are made earlier or in larger amounts than anticipated or are unanticipated, if anticipated revenues or cost-sharing arrangements do not materialize, or if funds are not otherwise available on acceptable terms. These and other risks, including those related to inability to comply with NASDAQ's continued listing requirements, the declining and generally unstable nature of current economic conditions; the results of discovery research and preclinical testing; the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA , European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data); uncertainties regarding the status of biotechnology patents; uncertainties as to the cost of protecting intellectual property; changes in the status of the existing collaborative and licensing relationships; the ability of collaborators, licensees and other third parties to meet their obligations; market demand for products; scale up and marketing capabilities; competition; international operations; share price volatility; XOMA's financing needs and opportunities; and risks associated with XOMA's status as a Bermuda company, are described in more detail in XOMA's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.

CONTACT: XOMA Company and Investor Contact: Carol DeGuzman 510-204-7270 Cell: 510 717 4642 deguzman@xoma.com Porter Novelli Life Sciences Media Contact: Carolyn Hawley 619-849-5375 chawley@pnlifesciences.com

SRLS, •SeraCare lands HIV-research deals, expects more government contracts to come
at bizjournals.com(Wed 9:05am)

DSCO, •UPDATE - Discovery Labs says FDA agrees on lung drug program
at Reuters(Wed 8:17am)
•InPlay: Discovery Labs and FDA establish path for potential Surfaxin approval
Briefing.com(Wed 7:00am)
•Discovery Labs and FDA Establish Path for Potential Surfaxin Approval
GlobeNewswire(Wed 7:00am)

Link AEZS met phase III news 1.36
http://finance.yahoo.com/news/AEterna-Zentaris-Thorough-QT-prnews-672909156.html?x=0&.v=9

Hey there! You are so going to be on as asst mod!

Sure!

Right, keep the doors open until it's too crowded. I'll stay tuned. Scottrade $2-9 scan at the open. Also prmkt WL of upgrades, downgrades, ipo, eps, guidance, most %up/dn.

Great idea for a board di4 !

Bmarked

My problem is I love them in all price ranges. I mainly use equity feed and watch the $5 and under. I would hate to miss on one at .99 because we made a price rule.

While we are new, I don't think we will be too inundated with tickers, but if we do get nuts, we can do something about it then.

That was right on! Are you interested in assisting?

Shocked how fast they grew! I suppose this was a much needed service, do you want to assist?

ASTC hit 3.84 today! Congrats to everyone that got in this mornng!

Welcome everyone. Lots of new boardmarks for the first day!

I had to cut out right after the market closed but I hope everyone feels comfortable posting whatever they want here!

I haven't had a chance to see what was moving AH yet.

di4-how about over $1 stocks, or even $2 for the board? They're just too many stocks.

SNR buyout not going to move much

ASTC-nice 5Fib retracement 2.55 reversal to 3.70 now

EQLB flying this mornin already!!!!.26 new hod..already

gotta ya marked here baby!!!!:)

board marks growing fast ;)

Will SNR top at $2.74?

SNR 2.65

SNR 2.55

SNR 2.40

SNR News 2.30 Tuesday, September 29 2009 9:01 AM, EST Sunair Announces Proposed Merger With Massey Services PR Newswire    "US Press Releases "


DEERFIELD BEACH, Fla. , Sept. 29 /PRNewswire-FirstCall/ -- Sunair Services Corporation (AMEX: SNR) today announced that it has entered into a definitive merger agreement with Massey Services, Inc. pursuant to which Massey would acquire all of the outstanding common stock of Sunair in an all-cash transaction valued at $2.75 per share, which represents a premium of approximately 47% over the stock's closing price on September 25, 2009 . Massey's operations would merge with Middleton Pest Control, Inc. , a wholly owned subsidiary of Sunair with headquarters located in Orlando, Florida , which provides pest control and lawn care services to both residential and commercial customers. The transaction is expected to close in November subject to the approval of Sunair's shareholders, customary regulatory approvals and other closing conditions. Following the closing, Harvey L. Massey will be the Chairman and CEO of the combined companies, which will be privately held.



Massey Services is headquartered in Orlando, Florida and provides residential and commercial pest control services, termite protection and lawn, tree and shrub care services in Florida , Georgia and Louisiana . Massey is a shareholder of Sunair and owns approximately 9.63% of Sunair's common stock.



Sunair Chairman, Richard C. Rochon commented that "Sunair's board of directors has concluded a lengthy evaluation of numerous strategic alternatives to enhance shareholder value and has concluded that joining forces with Massey is in the best interests of our shareholders." Massey Chairman, Harvey L. Massey , said "we believe the new organization created by this merger will build upon the complimentary strengths of both companies to provide superior value for our customers, employees and all stakeholders."



Hyde Park Capital is acting as Sunair's financial advisor, Akerman Senterfitt is acting as Sunair's legal counsel, and Shuffield Lowman is acting as Massey's legal counsel.



About Sunair

Sunair Services Corporation , a Florida corporation, through its wholly owned subsidiary, Middleton Pest Control, Inc. , with headquarters located in Orlando, Florida , provides pest control and lawn care services to both residential and commercial customers. Middleton provides essential pest control services and protection against termites and insects to homes and businesses. In addition, Middleton supplies lawn care services to homes and businesses, which includes fertilization treatments and protection against disease, weeds and insects for lawns and shrubs. For more information about Sunair, please visit http://www.sunairservices.com.



Cautionary Note Regarding Forward-looking Statements

This release contains one or more forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, the expected timing of the closing of the transaction. Forward-looking statements are identified by words such as "will," "expected," "believe" and other similar words. Sunair cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. A variety of known and unknown risks and uncertainties could cause actual results to differ materially from the anticipated results which include, but are not limited to: satisfaction of all regulatory and other conditions required for closing, the ability to obtain the approval of Sunair's shareholders, adverse developments in Sunair's business, and unanticipated expenses. In addition, other risks and uncertainties not presently known to us or that we consider immaterial could affect the accuracy of any such forward-looking statements. Sunair does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that exist after the date on which they were made. Additional risks and uncertainties include those detailed from time to time in Sunair's publicly filed documents, including its annual report on Form 10-K for its fiscal year ended September 30, 2008 .



Important Merger Information

This communication may be deemed to be solicitation material in respect of the proposed acquisition of Sunair by Massey Services, Inc. In connection with the proposed acquisition, Sunair intends to file a proxy statement on Schedule 14A with the Securities and Exchange Commission , or SEC , and Sunair intends to file other relevant materials with the SEC . Shareholders of Sunair are urged to read all relevant documents filed with the SEC when they become available, including Sunair's proxy statement, because they will contain important information about the proposed transaction, Sunair and Massey Services, Inc. A definitive proxy statement will be sent to holders of Sunair common stock seeking their approval of the proposed transaction. This communication is not a solicitation of a proxy from any security holder of Sunair.



Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC's web site, http://www.sec.gov. In addition, Sunair shareholders may obtain free copies of the documents filed with the SEC when available by contacting Edward M. Carriero, Jr. , Sunair's Chief Financial Officer, at (561) 208-7400. Such documents are not currently available. You may also read and copy any reports, statements and other information filed by Sunair with the SEC at the SEC public reference room at 100 F Street, N.E. Room 1580 , Washington, D.C. 20549. Please call the SEC at 1-800- SEC -0330 or visit the SEC's website for further information on its public reference room.



Sunair and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Sunair common stock in respect of the proposed transaction. Information about the directors and executive officers of Sunair is set forth in Sunair's proxy statement which was filed with the SEC on January 28, 2009 . Investors may obtain additional information regarding the interest of Sunair and its directors and executive officers in the proposed transaction by reading the proxy statement regarding the acquisition when it becomes available.



SOURCE Sunair Services Corporation

CERS News
Tuesday, September 29 2009 8:30 AM, EST Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting Business Wire    "US Press Releases "
CONCORD, Calif. --(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that it will present the proposed design for a U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets at the upcoming November meeting of the FDA's Blood Products Advisory Committee (BPAC). The Committee meeting is open to the public and discussion of the INTERCEPT trial is scheduled to occur the afternoon of November 16 . Information about Advisory Committee meetings is available from the FDA's website at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm.

"The proposed Phase III clinical trial design that we'll discuss with the Advisory Committee was created through close collaboration between Cerus and the FDA Office of Blood Review ," said Carol Moore , Cerus' vice president of regulatory affairs, quality and clinical affairs. "We look forward to presenting the result of this joint effort to BPAC, and hearing their views on this significant step forward toward defining a US approval pathway for INTERCEPT pathogen inactivated platelets."

Cerus has previously announced that an additional Phase III platelet trial was anticipated to be necessary for US approval.

The INTERCEPT platelet system was granted CE mark registration in 2002, and subsequently received additional European regulatory approvals in France (Afssaps), Switzerland (Swissmedic), Germany ( Paul Ehrlich Institute marketing authorization for the German Red Cross ).

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe , Russia , the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation .





Source: Cerus Corporation